Biomaterials in Organoid Research: Design Principles, Functional Regulation, and Clinical Translation

Abstract

Organoids, as three-dimensional (3D) in vitro models derived from stem cells, have revolutionized biomedical research  by recapitulating the physiological architecture and functional characteristics of native organs. However, the full  potential of organoids in disease modeling, drug discovery, and regenerative medicine remains constrained by inherent  challenges in reproducibility, functional maturation, and structural complexity—limitations predominantly attributed to  the inadequacy of conventional culture microenvironments. Biomaterials have emerged as indispensable tools to  address these bottlenecks, providing tunable platforms that deliver instructive biophysical and biochemical cues to  modulate cell fate determination, enhance tissue-level functionality, and improve experimental reproducibility. This  comprehensive review systematically elucidates the pivotal role of biomaterials in advancing organoid research, with a  focus on their design rationale, mechanisms of functional regulation, and translational pathways toward clinical  application. We delve into the diverse repertoire of natural and synthetic biomaterials, advanced biofabrication  strategies (e.g., 3D bioprinting and microfluidics), and how engineered matrices precisely tailor mechanical stiness,  biochemical composition, and electrical microenvironments to guide organoid development and functional maturation.  Furthermore, we highlight the broad spectrum of clinical applications, ranging from modeling complex pathologies  such as cancer and neurological disorders to enabling high-throughput drug screening and advancing regenerative  therapeutic strategies. Finally, we discuss current challenges, including standardization of culture protocols,  vascularization of organoids, and immune integration, and outline future perspectives for biomaterial-enhanced  organoids to realize their transformative potential in precision medicine and beyond.